Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
15 participants
INTERVENTIONAL
2008-09-30
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim is to study safety and activity of nelfinavir, added to standard chemoradiotherapy (28x1.8 Gy and capecitabine 825 mg/m2 BID) in patients with locally advanced rectal cancer. Furthermore analysis of the effect of nelfinavir combined with chemoradiation on tumor tissue will be studied.
Study design:
This is an open label, single-center phase I/II trial. During phase I the toxicity of 2 dose levels will be studied (750 mg BID and 1250 mg BID). During phase II the activity of nelfinavir in combination with capecitabine and radiotherapy will be studied, using the MTD from phase I. With respect to translational research, phosphorylation of Akt in monocytes and tumorcells will be measured at different timepoints during treatment. Furthermore, dynamic CT-PET scans will be obtained at different time points to get an impression of changes in SUV and perfusion during treatment and to correlate these changes with pathological response.
Study population:
Patients with locally advanced rectal cancer, who are candidates for chemoradiotherapy. In phase I, 6 patients will be included. In case of the occurrence of dose limiting toxicity, extra patients will be included, according to the rules described in the protocol. In phase II, 55 patients will be included.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
nelfinavir
see intervention
nelfinavir
Phase I:
* take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days
* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample
* day 0: PET-CT
Phase II:
* take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days
* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample
* day 7 biopsy
* day 7, 21 and week 15 :PET-CT + perfusion CT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nelfinavir
Phase I:
* take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days
* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample
* day 0: PET-CT
Phase II:
* take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days
* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample
* day 7 biopsy
* day 7, 21 and week 15 :PET-CT + perfusion CT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 18 years
* UICC T3-4 N0-2 M0
* WHO performance status 0-2
* Less than 10 % weight loss the last 6 months
* No recent (\< 3 months) severe cardiac disease (arrhythmia, congestive heart failure, infarction)
* Serum bilirubin = or \< 3x normal
* ASAT and ALAT = or \< 2,5x normal
* Creatinin clearance \>50 ml/min
* Willing and able to comply with the study prescriptions
* No history of prior pelvic radiotherapy
* No known HIV infection
* No hemophilia
* No concurrent medication that is metabolized by the CYP3A4 isoenzyme (calcium channel blockers, antifungal agents, macrolide antibiotics, gastrointestinal prokinetics, terfenadin, midazolam)
* Statins should be stopped (except pravastatin and fluvastatin),
* No concurrent use of St. John's Wort (Hypericum perforatum)
* Women should not be pregnant or lactating
* Being willing and able to undergo one extra biopsy
* Have given written informed consent before patient registration
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maastricht Radiation Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ph. Lambin, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Maastro Clinic, The Netherlands
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maastro clinic
Maastricht, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEC 07-03-026
Identifier Type: -
Identifier Source: org_study_id